پديد آورندگان :
Mostafavi Sayed Abolfazl نويسنده , Dormiani Kianoosh نويسنده , Khazaie Yahya نويسنده , Azmian Abbas نويسنده , Zargarzadeh Mohammad Reza نويسنده
چكيده لاتين :
The pharmacokinetic properties of amoxicillin and clavulanic acid when used alone
or in combination may be different and show interaction between these two agents
that might decrease the absolute bioavailability of clavulanic acid. In an open,
randomized, replicated Latin square under fasting condition, pharmacokinetics of
new formulations of amoxicillin/clavulanic acid were compared with a reference
formulation after single dose administration in 15 healthy male volunteers. Subjects
were given equal molar doses of new suspension formulations of
amoxicillin/clavulanic acid (312 mg/5 ml or 156 mg/5 ml) or Augmentin® (312 mg/5
ml) as the reference product. The wash-out period was one week between the
administrations of these antibacterial agents. Blood samples were collected exactly
before and after drug administration of each of the formulations at different time
points up to 6 h. The concentrations of the antibiotics in plasma were measured by
validated HPLC methods. Three formulations exhibited a similar mean Cmax of about
7.5±1.6 mg/l after Tmax of about 75±25 min. for amoxicillin and Cmax of about 2.5±0.6
mg/l after Tmax of about 61±15 min. for clavulanic acid. The AUC0-inf (total area
under the curve) for amoxicillin was about 1278±172 g.min/ml and it was about
354±66 g.min/ml for clavulanic acid. There were no significant differences in
pharmacokinetic parameters among these formulations. Pharmacokinetic parameters
of amoxicillin and clavulanic acid found in this study were similar to previously
published data. The two generic formulations investigated in this study proved to
be bioequivalent with brand-name Augmentin® with regard to the pharmacokinetic
parameters Cmax, AUC0-t, AUC0-inf and Tmax. Moreover, the parametric confidence
intervals (90%) for the ratio of the Cmax, Tmax, AUC0-t, and AUC0-Q values lie
between 0.8-1.2 based on log transformed values. We may conclude that the two
new formulations are bioequivalent with the reference suspension and could be
considered equally effective in medicinal practice. Moreover, there were no
interaction in pharmacokinetic parameters between amoxicillin and clavulanic
acid. No serious adverse event was observed with the studied drugs.